Wall Street analysts expect Minerva Neurosciences Inc (NASDAQ:NERV) to report earnings of ($0.41) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Minerva Neurosciences’ earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.49). Minerva Neurosciences reported earnings of ($0.34) per share in the same quarter last year, which indicates a negative year over year growth rate of 20.6%. The business is expected to report its next quarterly earnings results on Tuesday, March 10th.
On average, analysts expect that Minerva Neurosciences will report full year earnings of ($1.48) per share for the current fiscal year, with EPS estimates ranging from ($1.58) to ($1.44). For the next fiscal year, analysts forecast that the company will report earnings of ($1.69) per share, with EPS estimates ranging from ($3.32) to ($0.91). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Minerva Neurosciences.
Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Monday, November 4th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.01.
NERV has been the subject of several research reports. Chardan Capital reaffirmed a “buy” rating and set a $17.00 price objective on shares of Minerva Neurosciences in a research note on Tuesday, October 1st. BidaskClub raised shares of Minerva Neurosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, August 23rd. Zacks Investment Research cut Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Tuesday, October 29th. ValuEngine lowered Minerva Neurosciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 30th. Finally, William Blair started coverage on Minerva Neurosciences in a report on Wednesday, September 18th. They issued an “outperform” rating and a $26.00 price target for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $17.44.
NERV traded up $0.16 on Friday, reaching $5.72. 467,047 shares of the company’s stock were exchanged, compared to its average volume of 381,390. The stock has a market cap of $201.37 million, a PE ratio of -4.43 and a beta of 1.50. Minerva Neurosciences has a twelve month low of $4.01 and a twelve month high of $9.12. The stock’s fifty day moving average price is $4.73 and its 200-day moving average price is $6.03.
Institutional investors have recently added to or reduced their stakes in the stock. Quantitative Systematic Strategies LLC acquired a new stake in Minerva Neurosciences during the second quarter worth $62,000. TD Asset Management Inc. boosted its stake in Minerva Neurosciences by 2.8% during the second quarter. TD Asset Management Inc. now owns 58,847 shares of the biopharmaceutical company’s stock worth $331,000 after buying an additional 1,600 shares during the period. DekaBank Deutsche Girozentrale acquired a new stake in shares of Minerva Neurosciences during the second quarter valued at about $355,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Minerva Neurosciences during the second quarter valued at about $464,000. Finally, Acadian Asset Management LLC increased its position in shares of Minerva Neurosciences by 75.1% during the second quarter. Acadian Asset Management LLC now owns 58,024 shares of the biopharmaceutical company’s stock valued at $326,000 after acquiring an additional 24,890 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.
Further Reading: What is meant by holder of record?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.